Temporal trajectory of quality of life and its predictors in recipients of hematopoietic stem cell transplantation
This prospective longitudinal study evaluated the temporal trajectory of health-related quality of life (HRQOL) and its associated factors in patients who received hematopoietic stem cell transplantation (SCT) 6 months after transplantation. Eighty-nine adult patients who were admitted to Seoul National University Hospital for SCT were consecutively included in the study. The participants completed three standardized questionnaires: Insomnia Severity Index, Hospital Anxiety and Depression Scale, and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire. The participants completed the study questionnaires at three time points: before SCT (T1), immediately after SCT (T1), and 6 months after SCT (T3). Immediately after SCT, HRQOL decreased significantly (p < 0.001), followed by recovery over 6 months. The conditioning regimen for SCT showed no correlation with HRQOL at T2 (p = 0.283) or T3 (p = 0.799), with no significant difference in HRQOL between allogeneic and autologous SCT recipients at T2 (p = 0.829) or T3 (p = 0.824). Depression (p = 0.042), pain (p = 0.023), and appetite loss (p = 0.004) negatively influenced HRQOL at T1, whereas only pain (p = 0.048) remained an important factor at T2. Six months after SCT, the two most frequent symptoms, fatigue and financial problems, became major factors (p = 0.004 and p = 0.005, respectively). Depression began to play an important role in HRQOL again at T3 (p = 0.040). These findings demonstrate that SCT recipients need both psychological and medical support to achieve a better HRQOL after SCT.
KeywordsStem cell transplantation Quality of life Supportive care Distress
We thank our database manager, Mijin Yoon, for her accurate data management and BioMed Proofreading LLC for English editing. This work was supported by grants from the Seoul National University Hospital Research Fund (no. 0420160240) and Seoul National University College of Medicine (no. 800-20140171 to I.K.).
R.K. contributed substantially to the manuscript by conceiving and constructing the analytical project, interpreting the data, and writing the first draft of the manuscript. R.K., Y.C., Y.K., B.J.H., and I.K. designed the study. J.H., D.Y.S., Y.K., B.J.H., and I.K. recruited the patients and analyzed the data. R.K., K.L.S., K.M.L., B.J.H., and I.K. contributed to the data analysis and interpretation and read, edited, and approved the final manuscript. All of the authors reviewed and approved the initial and final versions of the manuscript.
Compliance with ethical standards
This protocol was approved by the Institutional Review Board at SNUH (IRB approval no. H-1005-043-318) and was conducted in accordance with Declaration of Helsinki provisions.
Conflicts of interest
The authors have no conflicts of interest to declare or other disclosures.
- 1.Fuji S, Loffler J, Savani BN, Einsele H, Kapp M (2016) Hyperglycemia as a possible risk factor for mold infections-the potential preventative role of intensified glucose control in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 52:657–662. https://doi.org/10.1038/bmt.2016.306 CrossRefPubMedGoogle Scholar
- 3.(1995) The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med (1982) 41(10):1403–1409Google Scholar
- 4.Worel N, Biener D, Kalhs P, Mitterbauer M, Keil F, Schulenburg A, Hocker P, Dieckmann K, Fischer G, Rosenmayr A, Linkesch W, Hinterberger W, Lechner K, Greinix HT (2002) Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantation. Bone Marrow Transplant 30(9):619–626. https://doi.org/10.1038/sj.bmt.1703677 CrossRefPubMedGoogle Scholar
- 13.Howell D, Olsen K (2011) Distress-the 6th vital sign. Curr Oncol (Toronto, Ont) 18(5):208–210Google Scholar
- 15.Bevans MF, Marden S, Leidy NK, Soeken K, Cusack G, Rivera P, Mayberry H, Bishop MR, Childs R, Barrett AJ (2006) Health-related quality of life in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 38(2):101–109. https://doi.org/10.1038/sj.bmt.1705406 CrossRefPubMedGoogle Scholar
- 16.Hjermstad MJ, Knobel H, Brinch L, Fayers PM, Loge JH, Holte H, Kaasa S (2004) A prospective study of health-related quality of life, fatigue, anxiety and depression 3-5 years after stem cell transplantation. Bone Marrow Transplant 34(3):257–266. https://doi.org/10.1038/sj.bmt.1704561 CrossRefPubMedGoogle Scholar
- 18.Braamse AM, Gerrits MM, van Meijel B, Visser O, van Oppen P, Boenink AD, Cuijpers P, Huijgens PC, Beekman AT, Dekker J (2012) Predictors of health-related quality of life in patients treated with auto- and allo-SCT for hematological malignancies. Bone Marrow Transplant 47(6):757–769. https://doi.org/10.1038/bmt.2011.130 CrossRefPubMedGoogle Scholar
- 19.Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376CrossRefPubMedGoogle Scholar
- 20.AN FPM, Bjordal K, Groenvold M, Curran D, Bottomley A, on, Group botEQoL (2001) The EORTC QLQ-C30 scoring manual, 3rd edn. European Organisation for Research and Treatment of Cancer, BrusselsGoogle Scholar
- 25.Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8):2912–2919. https://doi.org/10.1182/blood-2005-05-2004 CrossRefPubMedPubMedCentralGoogle Scholar
- 32.Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, Gilman PB, Shapiro CL (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309(13):1359–1367. https://doi.org/10.1001/jama.2013.2813 CrossRefPubMedPubMedCentralGoogle Scholar
- 38.McQuellon RP, Russell GB, Cella DF, Craven BL, Brady M, Bonomi A, Hurd DD (1997) Quality of life measurement in bone marrow transplantation: development of the functional assessment of cancer therapy-bone marrow transplant (FACT-BMT) scale. Bone Marrow Transplant 19(4):357–368. https://doi.org/10.1038/sj.bmt.1700672 CrossRefPubMedGoogle Scholar
- 39.McQuellon RP, Russell GB, Rambo TD, Craven BL, Radford J, Perry JJ, Cruz J, Hurd DD (1998) Quality of life and psychological distress of bone marrow transplant recipients: the 'time trajectory' to recovery over the first year. Bone Marrow Transplant 21(5):477–486. https://doi.org/10.1038/sj.bmt.1701115 CrossRefPubMedGoogle Scholar
- 40.Fiuza-Luces C, Simpson RJ, Ramírez M, Lucia A, Berger NA (2016) Physical function and quality of life in patients with chronic graft-versus-host-disease: a summary of preclinical and clinical studies and a call for exercise intervention trials in patients. Bone Marrow Transplant 51(1):13–26. https://doi.org/10.1038/bmt.2015.195 CrossRefPubMedGoogle Scholar